Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Influence of the Gut Microbiome on Blueberry Polyphenol Metabolites (BlueBIOME)

19 mei 2026 bijgewerkt door: Colorado State University
The objective of this study is to determine whether inter-individual differences in the gut microbiome influence exposure to blueberry polyphenol metabolites. We will use pharmacokinetics of blueberry polyphenols after an acute blueberry exposure to group individuals into "metabotypes", groups of individuals based on similarity in their metabolite profiles. We will then use multi-omic approaches to determine whether the gut microbiome predicts an individual's metabotype.

Studie Overzicht

Toestand

Werving

Gedetailleerde beschrijving

This study is an acute, single-arm polyphenol pharmacokinetic study designed to evaluate inter-individual variability in the metabolism of blueberry polyphenols and the role of the gut microbiome in shaping these responses. The study will be conducted at Colorado State University in the Food & Nutrition Clinical Research Laboratory. We will enroll approximately 125 healthy adults (≥18 years of age), with stratified recruitment across a range of ages and body mass index (BMI) values to capture diversity in gut microbiome composition. Participants will provide written informed consent prior to participation and will be compensated for their time.

Eligible participants will be generally healthy adults able to provide informed consent and adhere to study procedures. Key exclusion criteria include pregnancy or breastfeeding; pre-specified chronic diseases; recent antibiotic use; conditions affecting nutrient absorption; anemia; BMI ≤18.5 kg/m²; unwillingness to adhere to study protocols; recent blood draw within 1 week; participation in another research study; and contraindications to study procedures, treatments, or supplies.

The study consists of three main components: a screening visit, an acute test day, and a 24-hour follow-up visit. During the initial screening visit, participants will complete a health and medical history questionnaire, anthropometric assessments, blood pressure measurements, and a fasting blood draw to assess metabolic health and eligibility.

Following screening, participants will complete a short lead-in period prior to the test day, during which they will collect stool samples and a 24-hour urine sample at home and complete three 24-hour dietary recalls. They will also follow a low-polyphenol diet for three days prior to the test visit to minimize background variability in polyphenol exposure.

On the test day, participants will report to the laboratory following an overnight fast. Participants will consume a standardized blueberry beverage containing freeze-dried blueberry powder. Serial blood samples will be collected via an indwelling catheter at baseline and at multiple time points over an 8-hour period (0, 1, 2, 4, 6, and 8 hours) to characterize the pharmacokinetics of circulating blueberry polyphenol metabolites. Additional blood samples will be collected for peripheral blood mononuclear cell (PBMC) isolation at hours 4 and 6. Standardized low-polyphenol meals and snacks will be provided during the visit. Participants will also initiate a 24-hour urine collection and receive a stool collection kit for post-visit sampling.

Participants will return approximately 24 hours after blueberry consumption for a follow-up visit, which includes an additional fasting blood draw and return of urine and stool samples.

Throughout the study, additional data will be collected via validated questionnaires assessing gastrointestinal symptoms, sleep quality, physical activity, diet, and social determinants of health. Biological samples (blood, urine, and stool) will be used to assess polyphenol metabolism, gut microbiome composition and function, and related multi-omic profiles.

Studietype

Ingrijpend

Inschrijving (Geschat)

125

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Colorado
      • Fort Collins, Colorado, Verenigde Staten, 80523
        • Werving
        • Colorado State University; Food and Nutrition Clinical Research Laboratory; Gifford Building Room 216; 502 West Lake Street, Fort Collins, CO 80523
        • Hoofdonderzoeker:
          • Tiffany Weir, PhD
        • Contact:
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Healthy adults ≥18 years of age
  • Able and willing to provide informed consent
  • Willing and able to adhere to all study procedures and visit requirements

Exclusion Criteria:

  • Age <18 years
  • Pregnant or breastfeeding
  • Presence of chronic diseases, including but not limited to cardiovascular disease, diabetes, cancer, kidney, liver, gastrointestinal, or pancreatic disease
  • Use of medications for chronic diseases that may interfere with study outcomes
  • Any condition known to negatively impact nutrient absorption (e.g., inflammatory bowel disease, celiac disease, gastroparesis)
  • Anemia (hemoglobin <13.5 g/dL in men or <12.0 g/dL in women)
  • Body mass index (BMI) ≤18.5 kg/m²
  • Use of antibiotics within the past 2 months
  • Recent blood draw within 1 week prior to study participation
  • Currently participating in another research study involving a diet or exercise intervention
  • Known allergy or contraindication to blueberry products or study procedures
  • Unwilling or unable to comply with study requirements

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Single-arm
All participants will receive a single dose of the blueberry intervention to characterize pharmacokinetic profiles of polyphenol metabolites.
Participants will consume a single oral dose of a standardized blueberry beverage prepared with 22 g of freeze-dried blueberry powder reconstituted in approximately 480 mL of distilled water. The beverage will be consumed in its entirety at the start of the test visit following an overnight fast. This dose is selected to provide a defined quantity of blueberry-derived polyphenols for pharmacokinetic assessment. No additional interventions or comparator treatments will be administered.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pharmacokinetics - Area under the curve (AUC) of circulating blueberry polyphenol metabolites
Tijdsspanne: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
Pharmacokinetics - Area under the curve (AUC) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.
Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
Pharmacokinetics - Maximum concentration (Cmax) of circulating blueberry polyphenol metabolites
Tijdsspanne: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
Pharmacokinetics - Maximum concentration (Cmax) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.
Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
Pharmacokinetics - Time to maximum concentration (Tmax) of circulating blueberry polyphenol metabolites
Tijdsspanne: Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption
Pharmacokinetics - Time to maximum concentration (Tmax) will be calculated from plasma concentrations of blueberry-derived polyphenol metabolites, measured at serial time points following a single-dose blueberry intervention.
Baseline and 1, 2, 4, 6, 8 and 24 hours post-consumption

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Urinary excretion of blueberry polyphenol metabolites
Tijdsspanne: up to 24 hours post-consumption
Urinary concentrations of blueberry-derived polyphenol metabolites will be measured via 24-hour urine collection to assess excretion profiles following a single-dose blueberry intervention.
up to 24 hours post-consumption
Gut microbial taxonomic profiling
Tijdsspanne: Baseline
16s rRNA gene amplicon sequencing of stool samples will be used for exploratory gut microbial taxonomic profiling.
Baseline
Gut microbial functional potential
Tijdsspanne: Baseline
Metagenomic shotgun sequencing of stool samples will be used for exploratory profiling of gut microbial functional potential.
Baseline
Gut microbial transcripts
Tijdsspanne: Baseline
Metatranscriptomics will be used for exploratory profiling of gut microbial transcripts.
Baseline
Polyphenol Metabotype
Tijdsspanne: Baseline
Machine learning methods will be used to determine participant polyphenol metabotypes from pharmacokinetic profiles.
Baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

27 januari 2026

Primaire voltooiing (Geschat)

1 maart 2027

Studie voltooiing (Geschat)

1 januari 2028

Studieregistratiedata

Eerst ingediend

5 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

19 mei 2026

Eerst geplaatst (Werkelijk)

26 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

26 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

19 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 6959
  • 1RM1AT013318-01 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren